We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Allergan has entered into an exclusive licensing
agreement with Sanwa Kagaku Kenkyusho (Sanwa) to develop and commercialize POSURDEX
for the ophthalmic specialty market in Japan.
Onyx Pharmaceuticals and Bayer Pharmaceuticals plan to file a new drug application
(NDA) for cancer drug candidate BAY 43-9006, based on the results of a Phase
III study that showed the drug delayed the progress of the disease in patients
with advanced kidney cancer, Onyx said.
The recent flood of negative news about drug safety concerns has hurt the image
of drugmakers in the eyes of both consumers and physicians, but doctors also
say media attention has been blown out of proportion, a new poll finds.
The FDA was able to shave a significant amount of
time off the drug-approval process in 2004, despite approving 65 percent more
new product applications than in 2003, according to new figures released by
the agency.
The FDA is encouraging drugmakers to voluntarily submit pharmacogenomic data
as part of an initiative to speed the development of personalized therapies
based on patients' genetic profiles, according to a new final guidance.
Home Solutions Health, a market leader in providing a cost effective relief
from the discomfort of hemorrhoids via its patented and FDA approved HemorRelief
product, is announcing its intent to overhaul all of its core marketing materials
to better position the company in the overwhelming demanding marketplace.
BioTech Medics has closed on the $1.25 million acquisition of five FHJ Scientific
Inc.'s five U.S. letters of patent and related foreign patents covering a novel
compound solution.
Fujisawa Pharmaceutical announced on March 23 that the company has agreed with
API Corporation on the bulk production of Cefzon, Fujisawa's proprietary oral
cepharosporin antibiotic.
Israeli start-up Rosetta Genomics completed a $4 million financing round in
the past few days, its third, from private investors. Kadima High Tech, controlled
by Yossi Ben-Yosef, led the round.